A randomized double-blind control trial of moxifloxacin and levofloxacin in treatment of urinary tract infections
Abstract
AIM:To evaluate the efficacy and safety of moxifloxacin in the treatment of urinary tract infection. METHODS: A randomized double-blind control study (part 1) and an open label study (part 2) were conducted. In part 1, the patients in the treatment group received one moxifloxacin active tablet and one placebo tablet in the morning and two placebo tablets in the evening. The patients in the control group received two levofloxacin active tablets for 7-14 d. In part 2, the patients in the open group received one moxifloxacin active tablet po, qd for 7-14 d. RESULTS: The numbers of patients enrolled into moxifloxacin and levofloxacin group in the randomized double-blind control study and in the open study were 22, 22, 22, respectively. The numbers of patients for the efficacy analysis were 20, 20, 18, respectively. On 1 d after treatment, the clinical efficacy rates were 90 %, 95 %, 94 %, respectively; the bacterial efficacy rates were 84 %, 100 %, 100 %, respectively. Susceptibility testing showed that moxifloxacin and levofloxacin had the same high susceptibility rate and sensitivity rate, which were 82 % and 100 %, respectively. Adverse reaction rates were 23 %, 23 %, 14 % in the three groups, respectively. CONCLUSION:The results show that moxifloxacin is effective and safe in the treatment of urinary tract infection.
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design.
Read the paper
Related studies
- Association of lower urinary tract symptoms and OAB severity with quality of life and mental health in China, Taiwan and South Korea: results from a cross-sectional, population-based study
- Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter, Randomized, Parallel-Controlled Clinical Trial in China
- The Role of the NLR and PLR in Urinary Tract Infection
- Threat of Antimicrobial Resistance among Pilgrims with Infectious Diseases during Hajj: Lessons Learnt from COVID-19 Pandemic
- Leclercia adecarboxylata urinary tract infection in a patient with bladder cancer and recurrent hematuria
- A Case Series of Staphylococcus lugdunensis Infection in Cancer Patients at an Academic Cancer Institute in the United States
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.